{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:57:17Z","timestamp":1790402237965,"version":"4.1.0"},"reference-count":32,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2019,1,16]],"date-time":"2019-01-16T00:00:00Z","timestamp":1547596800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"DOI":"10.1371\/journal.pntd.0007026","type":"journal-article","created":{"date-parts":[[2019,1,16]],"date-time":"2019-01-16T18:36:52Z","timestamp":1547663812000},"page":"e0007026","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":28,"title":["Preclinical toxicity and pharmacokinetics of a new orally bioavailable flubendazole formulation and the impact for clinical trials and risk\/benefit to patients"],"prefix":"10.1371","volume":"13","author":[{"given":"Sophie","family":"Lachau-Durand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7683-8745","authenticated-orcid":true,"given":"Lieve","family":"Lammens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas-jan","family":"van der Leede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacky","family":"Van Gompel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Engelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Lampo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2019,1,16]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/mutage\/gev070","article-title":"Genotoxicity of flubendazole and its metabolites <italic>in vitro<\/italic> and the impact of a new formulation on <italic>in vivo<\/italic> aneugenicity","volume":"31","author":"DJ Tweats","year":"2016","journal-title":"Mutagenesis"},{"key":"ref2","first-page":"5","article-title":"Geary Flubendazole: a candidate macrofilaricide for lymphatic filariasis and onchocerciasis field programs","volume":"9","author":"Charles D Mackenzie","year":"2011","journal-title":"Expert Review of Anti-infective Therapy"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.reprotox.2014.06.009","article-title":"<italic>In vivo<\/italic> preliminary investigations of the effects of the benzimidazole anthelmintic drug flubendazole on rat embryos and fetuses","volume":"49","author":"M Longo","year":"2014","journal-title":"Reproductive Toxicology"},{"key":"ref4","article-title":"Data from: Preclinical toxicity and pharmacokinetics of a new orally bioavailable flubendazole formulation and the impact for clinical trials and risk\/benefit to patients","author":"S Lachau-Durand","year":"2018","journal-title":"Dryad Digital Repository"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0140-6736(83)92753-8","article-title":"Comparison of flubendazole and diethylcarbamazine in the treatment of onchocerciasis","volume":"321","author":"A Dominguez-Vazquez","year":"1983","journal-title":"Lancet"},{"issue":"5","key":"ref6","doi-asserted-by":"crossref","first-page":"e2838","DOI":"10.1371\/journal.pntd.0002838","article-title":"Exploring the potential of flubendazole in filariasis control: evaluation of the systemic exposure for different pharmaceutical preparations","volume":"8","author":"L Ceballos","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"H\u00fcbner MP, Ehrens A, Koschel M, Dubben B, Lenz F, Frohberger S et al. Macrofilaricidal efficacy of single and repeated oral and subcutaneous doses of flubendazole in Litomosoides sigmodontis infected jirds. Forthcoming 2018.","DOI":"10.1371\/journal.pntd.0006320"},{"issue":"5","key":"ref8","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3109\/15563650.2010.495348","article-title":"Colchicine poisoning: the dark side of an ancient drug","volume":"48","author":"Y Finkelstein","year":"2010","journal-title":"Clinical Toxicology"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0001-706X(03)00031-7","article-title":"Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics","volume":"86","author":"AD Dayan","year":"2003","journal-title":"Acta Tropica"},{"issue":"2","key":"ref10","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1177\/1091581815569582","article-title":"Preclinical studies on the pharmacokinetics, safety and toxicology of oxfendazole: toward first in human studies","volume":"34","author":"EE Codd","year":"2015","journal-title":"Int J Toxixol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/01926230490260655","article-title":"Possible mechanisms underlying the testicular toxicity of oxfendazole in rats","volume":"32","author":"M Okamura","year":"2004","journal-title":"Toxicologic Pathology"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"81","DOI":"10.4103\/1008-682X.122342","article-title":"Baumgartner A Male\u2011mediated developmental toxicity","volume":"16","author":"D Anderson","year":"2014","journal-title":"Asian Journal of Andrology"},{"key":"ref13","unstructured":"European Convention (ETS No. 123) for the protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes. Council Directive of November 24, 1986 (86\/609\/EEG) on the approximation of laws, regulations and administrative provisions of the Member States regarding the protection of animals used for experimental and other scientific purposes, complemented with the COMMISSION RECOMMENDATION of 18 June 2007 (2007\/526\/EC) on guidelines for the accommodation and care of animals used for experimental and other scientific purposes."},{"key":"ref14","unstructured":"Belgian Law (October 18, 1991): Protection of Vertebrate Animals used for Experimental and other Scientific Purposes. Royal Decree of November 14, 1993 for the protection of laboratory animals."},{"issue":"5","key":"ref15","first-page":"669","article-title":"Panel on euthanasia","volume":"218","year":"2001","journal-title":"JAVMA"},{"key":"ref16","unstructured":"International Conference on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. S7A Guideline on safety pharmacology studies for human pharmaceuticals (November 2000, issued as CPMP\/ICH\/539\/00\u2014ICH S7A; published in the Federal Register, Vol. 66, No. 135, July 13, 2001, pages 36791\u201336792)."},{"key":"ref17","unstructured":"ICH of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. S7B Guideline on non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals (May 2005, issued as CPMP\/ICH\/423\/02\u2014ICH S7B; published in the Federal Register, Vol. 70, No. 202, October 20, 2005, pages 61133\u201361134)."},{"key":"ref18","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/BF00401402","article-title":"Comprehensive observational assessment: 1a. A systematic, quantitative procedure for assessing the behavioural and physiologic state of the mouse","volume":"13","author":"S Irwin","year":"1968","journal-title":"Psychopharmacologia (Berl)"},{"key":"ref19","unstructured":"The Organization for Economic Co-operation and Development (OECD) Principles of Good Laboratory Practice concerning Mutual Acceptance of Data in the Assessment of Chemicals, 26 November 1997 (C(97) 186 Final)."},{"key":"ref20","unstructured":"EC Council Directive 2004 (2004\/10\/EC, February 11, 2004, Official Journal of February 20, 2004)"},{"key":"ref21","unstructured":"Bonnes Pratiques de Laboratoire, Minist\u00e8re de l\u2019Emploi et de la Solidarit\u00e9 Fran\u00e7aise, no. 2000\/5bis, arr\u00eat\u00e9 du 14\/03\/2000 (JO 23\/03\/2000)."},{"key":"ref22","unstructured":"OECD GLP consensus document 13 on \u201cthe application of the OECD principles of GLP to the organization and management of multi-site studies\u201d, ENV\/JM\/MONO (2002)9, 25 June 2002."},{"key":"ref23","unstructured":"European Agency for the Evaluation of Medicinal Products (2009) ICH Topic M3 (R2). \u2018\u2018Non-Clinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals\u201d."},{"key":"ref24","unstructured":"European Agency for the Evaluation of Medicinal Products (1995) ICH Topic S3 A\u2018\u2018Toxicokinetics: A Guidance for Assessing Systemic Exposure in Toxicology Studies\u201d. ICH Harmonised Tripartite Guideline."},{"key":"ref25","unstructured":"OECD Principles of Good Laboratory Practice (as revised in 1997) ENV\/MC\/CHEM (98)17."},{"key":"ref26","unstructured":"International Conference on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. S2(R1) document recommended for adoption at step 4 of the ICH process on 9 November 2011. Adopted at Step 5 in Europe by CHMP December 2011 (issued as EMA\/CHMP\/ICH\/126642\/2008). Adopted at Step 5 in US by FDA on June 7, 2012 (issued as 77 FR 33748 pages 33748\u201333749). Adopted in Japan at Step 5 on September 20, 2012 (issued as PFSB\/ELD Notification No. 0920\u20132). Guidance on genotoxicity testing and data interpretation for pharmaceuticals intended for human use."},{"key":"ref27","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/0165-1161(75)90046-1","article-title":"Methods for detecting carcinogens and mutagens with the salmonella\/mammalian microsome mutagenicity test","volume":"31","author":"BN Ames","year":"1975","journal-title":"Mutation Research"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0165-1161(76)90076-5","article-title":"Mutagen testing using trp+ reversion in Escherichia coli","volume":"38","author":"MHL Green","year":"1976","journal-title":"Mutation"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0165-1161(83)90010-9","article-title":"Revised methods for the Salmonella mutagenicity test","volume":"113","author":"DM Maron","year":"1983","journal-title":"Mutation Research"},{"key":"ref30","unstructured":"OECD for Testing of Chemicals, Guideline 471 (Genetic Toxicology: Bacterial Reverse Mutation Test), Ninth Addendum to the OECD Guidelines for the Testing of Chemicals, adopted July 21, 1997."},{"key":"ref31","unstructured":"US FDA Good Laboratory Practice Regulations as published in 21 CFR Part 58."},{"key":"ref32","unstructured":"OECD Guidelines for Testing of Chemicals, Guideline 474 (Mammalian Erythrocyte Micronucleus Test), adopted July 21, 1997."}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pntd.0007026","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T08:00:41Z","timestamp":1589011241000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0007026"}},"subtitle":[],"editor":[{"given":"Jennifer","family":"Keiser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,1,16]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,1,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0007026","relation":{},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,16]]}}}